Description: KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Home Page: www.kalarx.com
1167 Massachusetts Avenue
Arlington,
MA
02476
United States
Phone:
781 996 5252
Officers
| Name | Title |
|---|---|
| Mr. Mark T. Iwicki | Chairman & CEO |
| Mr. Todd Bazemore | President & COO |
| Dr. R. Kim Brazzell Ph.D. | Head of R&D and Chief Medical Officer |
| Dr. Justin Hanes Ph.D. | Founder & Chair of the Scientific Advisory Board |
| Ms. Mary Reumuth CPA | CFO & Treasurer |
| Ms. Jill S. Steier | Executive Director of Investor Relations & Corporate Communications |
| Mr. Vincent Kosewski | Senior VP of Manufacturing & Supply Chain Management |
| Mr. Darius Kharabi J.D., M.B.A. | Chief Business Officer |
| Dr. Francis S. Mah M.D. | Chief Medical Advisor |
| Mr. Josiah Craver | Senior VP & Corporate Controller |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.1763 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 43 |